Singh SK - Search Results

1

Impact of product-related factors on immunogenicity of biotherapeutics.

Singh SK. Singh SK. J Pharm Sci. 2011 Feb;100(2):354-87. doi: 10.1002/jps.22276. Epub 2010 Aug 25. J Pharm Sci. 2011. PMID: 20740683 Review.

2

Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions.

Kumar S, Singh SK, Wang X, Rup B, Gill D. Kumar S, et al. Among authors: singh sk. Pharm Res. 2011 May;28(5):949-61. doi: 10.1007/s11095-011-0414-9. Epub 2011 Mar 25. Pharm Res. 2011. PMID: 21437790

3

An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics.

Singh SK, Afonina N, Awwad M, Bechtold-Peters K, Blue JT, Chou D, Cromwell M, Krause HJ, Mahler HC, Meyer BK, Narhi L, Nesta DP, Spitznagel T. Singh SK, et al. J Pharm Sci. 2010 Aug;99(8):3302-21. doi: 10.1002/jps.22097. J Pharm Sci. 2010. PMID: 20310025 Review.

4

Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and Strategy.

Narhi LO, Corvari V, Ripple DC, Afonina N, Cecchini I, Defelippis MR, Garidel P, Herre A, Koulov AV, Lubiniecki T, Mahler HC, Mangiagalli P, Nesta D, Perez-Ramirez B, Polozova A, Rossi M, Schmidt R, Simler R, Singh S, Spitznagel TM, Weiskopf A, Wuchner K. Narhi LO, et al. J Pharm Sci. 2015 Jun;104(6):1899-1908. doi: 10.1002/jps.24437. Epub 2015 Apr 1. J Pharm Sci. 2015. PMID: 25832583 Review.

5

Relationship between potential aggregation-prone regions and HLA-DR-binding T-cell immune epitopes: implications for rational design of novel and follow-on therapeutic antibodies.

Kumar S, Mitchell MA, Rup B, Singh SK. Kumar S, et al. Among authors: singh sk. J Pharm Sci. 2012 Aug;101(8):2686-701. doi: 10.1002/jps.23169. Epub 2012 May 22. J Pharm Sci. 2012. PMID: 22619033

6

Antibody structure, instability, and formulation.

Wang W, Singh S, Zeng DL, King K, Nema S. Wang W, et al. J Pharm Sci. 2007 Jan;96(1):1-26. doi: 10.1002/jps.20727. J Pharm Sci. 2007. PMID: 16998873 Review.

7

Immunogenicity of protein aggregates--concerns and realities.

Wang W, Singh SK, Li N, Toler MR, King KR, Nema S. Wang W, et al. Among authors: singh sk. Int J Pharm. 2012 Jul 15;431(1-2):1-11. doi: 10.1016/j.ijpharm.2012.04.040. Epub 2012 Apr 21. Int J Pharm. 2012. PMID: 22546296 Review.

8

Comparative evaluation of disodium edetate and diethylenetriaminepentaacetic acid as iron chelators to prevent metal-catalyzed destabilization of a therapeutic monoclonal antibody.

Zhou S, Zhang B, Sturm E, Teagarden DL, Schöneich C, Kolhe P, Lewis LM, Muralidhara BK, Singh SK. Zhou S, et al. Among authors: singh sk. J Pharm Sci. 2010 Oct;99(10):4239-50. doi: 10.1002/jps.22141. J Pharm Sci. 2010. PMID: 20737631

9

Impact of extractables/leachables from filters on stability of protein formulations.

Huang M, Horwitz TS, Zweiben C, Singh SK. Huang M, et al. Among authors: singh sk. J Pharm Sci. 2011 Nov;100(11):4617-30. doi: 10.1002/jps.22670. Epub 2011 Jun 21. J Pharm Sci. 2011. PMID: 21695696

10

Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation-prone regions.

Agrawal NJ, Kumar S, Wang X, Helk B, Singh SK, Trout BL. Agrawal NJ, et al. Among authors: singh sk. J Pharm Sci. 2011 Dec;100(12):5081-95. doi: 10.1002/jps.22705. Epub 2011 Jul 24. J Pharm Sci. 2011. PMID: 21789769 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,496 results

Search Page